NASDAQ:BDSI - BioDelivery Sciences International Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.11 -0.19 (-3.58 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$5.11
Today's Range$5.07 - $5.31
52-Week Range$1.70 - $5.36
Volume841,041 shs
Average Volume1.27 million shs
Market Capitalization$362.55 million
P/E Ratio-7.00
Dividend YieldN/A
Beta0.45
BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$55.64 million
Book Value$0.42 per share

Profitability

Net Income$-33,870,000.00

Miscellaneous

EmployeesN/A
Market Cap$362.55 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its earnings results on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The specialty pharmaceutical company had revenue of $12.18 million for the quarter, compared to the consensus estimate of $12.44 million. BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. View BioDelivery Sciences International's Earnings History.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for BioDelivery Sciences International.

What price target have analysts set for BDSI?

5 brokers have issued 1 year price targets for BioDelivery Sciences International's stock. Their forecasts range from $4.00 to $8.00. On average, they expect BioDelivery Sciences International's share price to reach $6.00 in the next year. This suggests a possible upside of 17.4% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.

What is the consensus analysts' recommendation for BioDelivery Sciences International?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioDelivery Sciences International.

What are Wall Street analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
  • 1. According to Zacks Investment Research, "BioDelivery reported decent fourth-quarter results wherein earnings came in line with estimates and sales beat estimates. The company secured improved positioning in several managed care contracts, providing preferred access to Belbuca. The company’s efforts have brought 115 million patients under preferred coverage so far in 2019, having started 2018 with 7 million. The company’s efforts boosted the drug’s sales and profitability in 2018. Belbuca’s prescriptions grew sequentially in every quarter of 2018. Increase in sales force supported the growth. BioDelivery’s shares have outperformed the industry so far this year. However, given the lackluster performance of Bunavail, BioDelivery has decided to reduce spending on the drug. Moreover, the company’s portfolio and its pipeline may face severe competition as these target a highly genericized and crowded market." (3/20/2019)
  • 2. HC Wainwright analysts commented, "Our $6 12-month target (from $5) is based on a DCF reflecting strong Belbuca growth to nearly $180M by 2022, company cash-flow breakeven by end-2019, and overall profitability in 2020. Our DCF reflects a 10% WACC discount and negative -15% terminal value beyond 2026, and includes 90M fully diluted shares vs. currently reported 70M) to account for, among other shares, the substantial dilution from convertible preferred series B shares that were issued in the 2018 $50M financing ($1.80/share conversion price)." (3/15/2019)
  • 3. Cantor Fitzgerald analysts commented, ". Post 4Q18, we are reiterating our Overweight rating and our 12-month price target of $8. We view BDSI as a Belbuca execution story, and the company is exceeding its execution goals as well as our expectations. BDSI continues to execute on its commercial plan to drive continued growth of Belbuca, such that we believe investors will be rewarded by the company’s solid execution in 2019 and beyond, which should drive upward earnings revisions and further upside in BDSI’s stock." (3/14/2019)

Has BioDelivery Sciences International been receiving favorable news coverage?

News stories about BDSI stock have been trending somewhat negative on Saturday, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioDelivery Sciences International earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of BioDelivery Sciences International's key competitors?

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD) and Verastem (VSTM).

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the folowing people:
  • Herm Cukier, Chief Executive Officer & Director
  • Scott M. Plesha, President & Chief Commercial Officer
  • Joseph Lockhart, Senior Vice President-Operations
  • Mary Theresa Coelho, Chief Financial Officer
  • Paul Blake, Senior VP-Clinical Research & Regulatory Affairs

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (6.67%), Stonepine Capital Management LLC (5.62%), Nantahala Capital Management LLC (3.86%), BlackRock Inc. (1.96%), Millennium Management LLC (1.39%) and 1492 Capital Management LLC (1.25%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht and Paolantonio Ernest Robert De. View Institutional Ownership Trends for BioDelivery Sciences International.

Which major investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Stonepine Capital Management LLC, Fosun International Ltd, Foresite Capital Management II LLC, Essex Investment Management Co. LLC and Valley National Advisers Inc.. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Mark A Sirgo and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.

Which major investors are buying BioDelivery Sciences International stock?

BDSI stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Millennium Management LLC, Pura Vida Investments LLC, 1492 Capital Management LLC, Barclays PLC, D. E. Shaw & Co. Inc., Penn Capital Management Co. Inc. and BlackRock Inc.. View Insider Buying and Selling for BioDelivery Sciences International.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $5.11.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $362.55 million and generates $55.64 million in revenue each year. The specialty pharmaceutical company earns $-33,870,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is http://www.bdsi.com.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]


MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  441 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  695
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Featured Article: The risks of owning bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel